Safingol is under clinical development by CerRx and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Safingol’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Safingol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Safingol is under development for the treatment of adult non-Hodgkin's lymphoma and solid tumor. It is administered by intravenous route. The drug candidate acts by targeting protein kinase C. Safingol is a saturated derivative of sphingosine. It resembles the normal precursor molecule of dihydroceramides, called sphinganine.
CerRx is a drug discovery company that discovers and develops anticancer drugs for cancer patients. The company provides products such as fenretinide, safingol and ppmp. Its fenretinide is synthesized from vitamin A, contains low level of bone marrow toxicity and increases ceramide waxes in cancer cells to prevent further growth and kills cancer cells. CerRx’s safingol is an artificial ceramide precursor that prevents cancer by killing fenretinide in cancer cells. The company develops therapeutics to stimulate overproduction of ceramides in cancer cells. It also conducts various research and development programs. CerRx is headquartered in Lubbock, Texas, the US.
Quick View Safingol LOA Data
|Highest Development Stage|